Cargando…
From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
The Ras-dependent Raf/MEK/ERK1/2 mitogen-activated protein (MAP) kinase signaling pathway is a major regulator of cell proliferation and survival. Not surprisingly, hyperactivation of this pathway is frequently observed in human malignancies as a result of aberrant activation of receptor tyrosine ki...
Autores principales: | Frémin, Christophe, Meloche, Sylvain |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2830959/ https://www.ncbi.nlm.nih.gov/pubmed/20149254 http://dx.doi.org/10.1186/1756-8722-3-8 |
Ejemplares similares
-
The MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control
por: Guégan, Jean-Philippe, et al.
Publicado: (2012) -
Phosphoproteome dynamics reveal novel ERK1/2 MAP kinase substrates with broad spectrum of functions
por: Courcelles, Mathieu, et al.
Publicado: (2013) -
Redundancy in the World of MAP Kinases: All for One
por: Saba-El-Leil, Marc K., et al.
Publicado: (2016) -
Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors
por: Voisin, Laure, et al.
Publicado: (2008) -
Current Development Status of MEK Inhibitors
por: Cheng, Ying, et al.
Publicado: (2017)